CemiplimAb Survivorship Epidemiology
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
287actual
Sites
53
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-06-27 | actual | When the study began enrolling |
| Primary completion | 2025-09-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-29 | actual | The whole study's end, after follow-up |
| First posted | 2019-02-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cutaneous Squamous Cell Carcinoma
- Basal Cell Carcinoma
Intervention
- Drug: cemiplimab — also filed as REGN2810, Libtayo
Primary outcomes
what the primary-completion date above is the date OFObjective response rate (ORR)
measured Up to 36 months
Disease control rate (DCR)
measured Up to 36 months
Duration of response (DOR)
measured Up to 36 months
Time to response
measured Up to 36 months
Progression free survival (PFS)
measured Up to 36 months
Overall Survival (OS)
measured Up to 36 months
Time to treatment failure (TTTF)
measured Up to 36 months
Disease specific death (DSD)
measured Up to 36 months
Number of patients with metastatic vs locally advanced cancer summarized every three weeks
measured Up to 36 months
Immune related adverse events (irAEs)
measured Up to 36 months
Infusion related reactions (IRRs)
measured Up to 36 months
Treatment related serious adverse reactions (SARs)
measured Up to 36 months
Publications
- PMID 39797702 — linked by the registry
- PMID 31951149 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed